# Tempus AI earnings, Personalis acquisition, and pricing news

> Live situation record from CLSTR: https://clstr.news/situations/tempus-ai-earnings-and-insider-sales
> Updated: 2026-09-17T21:16:49.000Z. Sources: 10. Developments: 6.

In early August 2026, Tempus AI reported a 22% year-over-year increase in second-quarter revenue to $382.5 million, driven by growth in diagnostics and data-applications. While the company posted its first quarterly profit of $5.64 million, the result was primarily driven by approximately $103 million in “other income”—largely unrealized gains from holdings like Recursion and Personalis—which offset an operating loss of $75.91 million. 

Investor sentiment shifted upward following a $1.5 billion agreement to acquire Personalis, intended to integrate genetic sequencing capabilities for personalized cancer vaccines being developed by Moderna and Merck. This led BTIG Research to upgrade the stock with an $80 price target. By late August, shares surged 39.5% in a single week following positive Phase 3 clinical trial results for the Merck and Moderna mRNA cancer vaccine, which showed a reduction in cancer return when used with Keytruda.

In mid-September, shares rose 14.85% to $80.36 after CEO Eric Lefkofsky announced plans at the Morgan Stanley Global Healthcare Conference to transition solid tumor testing to an ADLT pricing structure by 2027. This transition could increase xT tumor test prices from $2,923 to $4,500, with a potential annual revenue impact of $80 million to $100 million. Additionally, potential price increases for xF liquid biopsy products could impact annual revenue by $250 million to $300 million by late 2027. Throughout these periods, various executives, including Ryan Fukushima and Nadja West, conducted share sales under pre-arranged Rule 10b5-1 plans.

## Timeline

### 2026-09-17: Tempus AI shares surge on planned diagnostic price increases

Tempus AI shares surged nearly 15% following plans to increase diagnostic testing prices for solid tumors and liquid biopsies, despite recent insider stock sales by the CEO.

2 sources. https://clstr.news/cluster/tempus-ai-shares-surge-on-diagnostic-pricing-increase-plans

### 2026-08-22: Tempus AI shares surge following Merck and Moderna cancer vaccine trial results

Tempus AI stock rose nearly 40% following successful Phase 3 trial results for a Merck and Moderna cancer vaccine, validating technology from Personalis, which Tempus is set to acquire.

4 sources. https://clstr.news/cluster/tempus-ai-shares-surge-following-merck-and-moderna-cancer-vaccine-trial-results

### 2026-08-19: Tempus AI shares rise following BTIG analyst upgrade and Personalis deal

Tempus AI shares rose following a BTIG Research upgrade to an $80 price target, driven by optimism over its $1.5 billion acquisition of Personalis and potential sequencing roles for cancer vaccines.

2 sources. https://clstr.news/cluster/tempus-ai-shares-rise-following-btig-analyst-upgrade-and-personalis-deal

### 2026-08-17: Tempus AI reports first quarterly profit driven by non-operating income

Tempus AI reported its first quarterly profit in Q2 2026, driven by $103 million in non-operating income and unrealized gains, despite an operating loss in its core AI healthcare business.

2 sources. https://clstr.news/cluster/tempus-ai-reports-first-quarterly-profit-driven-by-non-operating-income

### 2026-08-05: Tempus AI CEO and Director Disclose August Share Sales

Tempus AI CEO Ryan Fukushima sold 23,818 shares for $1.1 million and Director David Epstein sold 370 shares for $16,000 on Aug 3, both under Rule 10b5‑1 plans, reducing their holdings.

2 sources. https://clstr.news/cluster/tempus-ai-ceo-and-director-disclose-august-share-sales

### 2026-08-01: Tempus AI posts 22% Q2 revenue rise, secures new institutional stake

Tempus AI posted 22% Q2 revenue growth to $382.5 M, GAAP net income $5.6 M and FDA approval for tumor‑only xT CDx, while Avidity Partners added a $1.1 M stake.

2 sources. https://clstr.news/cluster/tempus-ai-posts-22-q2-revenue-rise-secures-new-institutional-stake

---
Cite as: Tempus AI earnings, Personalis acquisition, and pricing news. CLSTR, https://clstr.news/situations/tempus-ai-earnings-and-insider-sales